NEWER ADVANCES IN MESENCHYMAL STEM CELL THERAPY
In the modern world, overcoming diseases are more challenging and newer ways are being discovered to give high quality of patient care, on the basis of scientific experimentation and applicative studies undertaken by various institutes and organizations. Mesenchymal stem cells (MSCs) are procured through many body origins usually by the placenta as well as the umbilical cord but other sources like bone core derived MSCs are also important as each source will give the cells its own characteristic features. MSCs play a very important role in the scenario with their multi-lineage potency that can either directly or indirectly by acting on cytokines or growth factors can cause cell regeneration process and hold great possibility of wound repair, treating spinal cord injuries, and treating auto immune diseases by immunomodulation. MSCs can give incredible help in case of bone, cartilage or tissue related defects, injuries or disorders that may be corrected or repaired through it. They can be employed in various heart related complications, bacterial activity, sepsis, liver dysfunctions, diabetes, and even prove useful in cancer. Various procedures either physiological or surgical are present including cell therapies, tissue, and osteo-engineering and immune targeted experimentations that can treat the diseases as well as ensure complete recovery.
2. Owen M. Lineage of osteogenic cells and their relationship to the stromal system. In: Peck WA, editor. Bone and Mineral Research. Vol. 3. New York: Elsevier; 1985. p. 1-25.
3. Caplan A. Mesenchymal stem cells. J Orthop Res 1991;9:641-50.
4. Somerman M, Hewitt AT, Varner HH, Schiffman E, Termine J, Reddi AH. Identification of a bone matrix-derived chemotactic factor. Calcif Tissue Int 1983;35:481-5.
5. Jose JM, Alejandro EL, Paulette C. Minireview Mesenchymal Stem Cells. United States: Pennsylvania State University; 2001.
6. Wang H, Hung SC, Peng ST, Huang CC, Wei HM, Guo YJ, et al. Mesenchymal stem cells in the Wharton’s jelly of the human umbilical cord. Stem Cells 2004;22:1330-7.
7. Wang JS, Shum-Tim D, Galipeau J, Chedrawy E, Eliopoulos N, Chiu RC. Marrow stromal cells for cellular cardiomyoplasty: Feasibility and potential clinical advantages. J Thorac Cardiovasc Surg 2000;120:999-1005.
8. Anker PS, Scherjon SA, Kleijburg-van der Keur C, de Groot-Swings GM, Claas FH, Fibbe WE, et al. Isolation of mesenchymal stem cells of fetal or maternal origin from human placenta. Stem Cells 2004;22:1338-45.
9. Dang ZC, van Bezooijen RL, Karperien M, Papapoulos SE, Löwik CW.Exposure of KS483 cells to estrogen enhances osteogenesis and inhibits adipogenesis. J Bone Miner Res 2002;17:394-405.
10. Rocky ST, Genevieve B, Richard T. Adult mesenchymal stem cells and cell-based tissue engineering. Arthritis Res Ther 2003;5:32-45.
11. Majors AK, Boehm CA, Nitto H, Midura RJ, Muschler GF. Characterization of human bone marrow stromal cells with respect to osteoblastic differentiation. J Orthop Res 1997;15:546-57.
12. Sethe S, Scutt A, Stolzing A. Aging of mesenchymal stem cells. Ageing Res Rev 2006;5:91-116.
13. Sames K, Sethe S, Stolzing A. Extending the lifespan: Biotechnical, Gerontological, and Social Problems (Medizin and Gesellschaft). Münster, Germany: Lit Verlag; 2005.
14. Barry F, Murphy J. Mesenchymal stem cells: Clinical applications and biological characterization. Int J Biochem Cell Biol 2004;36:568-84.
15. Digirolamo CM, Stokes D, Colter D, Phinney DG, Class R, Prockop DJ. Propagation and senescence of human marrow stromal cells in culture: A simple colony-forming assay identifies samples with the greatest potential to propagate and differentiate. Br J Haematol 1999;107:275-81.
16. Pittenger M, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, et al. Multilineage potential of adult human mesenchymal stem cells. J Electrochem Soc 1987;58:3442.
17. Manas KM, Banks V, Peluso DP, Morris EA. Isolation, characterization, and chondrogenic potential of human bone marrow-derived multipotential stromal cells. J Cell Physiol 2000;185:98-106.
18. Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol 2008;8:726-36.
19. Muguruma Y, Yahata T, Miyatake H, Sato T, Uno T, Itoh J, et al. Reconstitution of the functional human hematopoietic microenvironment derived from human mesenchymal stem cells in the murine bone marrow compartment. Blood 2006;107:1878-87.
20. Kumar S, Chanda D, Ponnazhagan S. Therapeutic potential of genetically modified mesenchymal stem cells. Gene Ther 2008;15:711-5.
21. Osyczka AM, Diefenderfer DL, Bhargave G, Leboy PS. Different effects of BMP-2 on marrow stromal cells from human and rat bone. Cells Tissues Organs 2004;176:109-19.
22. Maxson S, Lopez EA, Yoo D, Danilkovitch-Miagkova A, Leroux MA. Concise review: Role of mesenchymal stem cells in wound repair. Stem Cells Transl Med 2012;1:142-9.
23. Hanson SE, Bentz ML, Hematti P. Mesenchymal stem cell therapy for nonhealing cutaneous wounds. Plast Reconstr Surg 2010;125:510-6.
24. Mustoe TA, O’Shaughnessy K, Kloeters O. Chronic wound pathogenesis and current treatment strategies: A unifying hypothesis. Plast Reconstr Surg 2006;117:35S-41S.
25. Wu Y, Chen L, Scott PG, Tredget EE. Mesenchymal stem cells enhance wound healing through differentiation and angiogenesis. Stem Cells 2007;25:2648-59.
26. Du Z, Podsypanina K, Huang S, McGrath A, Toneff MJ, Bogoslovskaia E, et al. Introduction of oncogenes into mammary glands in vivo with an avian retroviral vector initiates and promotes carcinogenesis in mouse models. Proc Natl Acad Sci U S A 2006;103:17396-401.
27. Otero-Viñas M, Falanga V. Mesenchymal stem cells in chronic wounds: The spectrum from basic to advanced therapy. Adv Wound Care (New Rochelle) 2016;5:149-63.
28. Falanga V, Brem H, Ennis WJ, Wolcott R, Gould LJ, Ayello EA. Maintenance debridement in the treatment of difficult-to-heal chronic wounds. Recommendations of an expert panel. Ostomy Wound Manage 2008;13:14-5.
29. DiMarino A, Caplan A, Bonfield T. Mesenchymal stem cells in tissue repair. Front Immunol 2013;4:201.
30. Caplan A. Adult mesenchymal stem cells for tissue engineering versus regenerative medicine. J Cell Physiol 2007;213:341-7.
31. Dennis JE, Haynesworth SE, Young RG, Caplan AI. Osteogenesis in marrow-derived mesenchymal cell porous ceramic composites transplanted subcutaneously: Effect of fibronectin and laminin on cell retention and rate of osteogenic expression. Cell Transplant 1992;1:23-32.
32. Dennis JE, Konstantakos EK, Arm D, Caplan AI. In vivo osteogenesis assay: A rapid method for quantitative analysis. Biomaterials 1998;19:1323-8.
33. Ohgushi H, Caplan AI. Stem cell technology and bioceramics: From cell to gene engineering. J Biomed Mater Res 1999;48:913-27.
34. Solchaga LA, Yoo JU, Lundberg M, Dennis JE, Huibregtse BA, Goldberg VM, et al. Hyaluronan-based polymers in the treatment of osteochondral defects. J Orthop Res 2000;18:773-80.
35. Hui JH, Ouyang H, Hutmacher D, Goh JC, Lee EH. Mesenchymal stem cells in musculoskeletal tissue engineering: A review of recent advances in national university of Singapore. Ann Acad Med Singapore 2005;34:206-12.
36. Mazock JB, Schow SR, Triplett RG. Posterior iliac crest bone harvest: Review of technique, complications, and use of an epidural catheter for postoperative pain control. J Oral Maxillofac Surg 2003;61:1497-503.
37. Wang X, Wang Y, Gou W, Lu Q, Peng J, Lu S. Role of mesenchymal stem cells in bone regeneration and fracture repair: A review. Int Orthop 2013;37:2491-8.
38. Myers TJ, Yan Y, Granero-Molto F, Weis JA, Longobardi L, Li T, et al. Systemically delivered insulin-like growth factor-I enhances mesenchymal stem cell-dependent fracture healing. Growth Factors 2012;30:230-41.
39. Di Bernardo G, Galderisi U, Fiorito C, Squillaro T, Cito L, Cipollaro M, et al. Dual role of parathyroid hormone in endothelial progenitor cells and marrow stromal mesenchymal stem cells. J Cell Physiol 2010;222:474-80.
40. Arnold IC. Review: Mesenchymal stem cells: Cell-based reconstructive therapy in orthopedics. Tissue Eng 2005;11:1198-211.
41. Abbas S, Seyedjafari E, Soleimani M, Ahmadbeigi N, Dinarvand P, Ghaemi N. A comparison between osteogenic differentiation of human unrestricted somatic stem cells and mesenchymal stem cells from bone marrow and adipose tissue. Biotechnol Lett 2011;33:1257-64.
42. Seong JM, Kim BC, Park JH, Kwon IK, Mantalaris A, Hwang YS. Stem cells in bone tissue engineering. Biomed Mater 2010;5:062001.
43. Sharma RI, Snedeker JG. Biochemical and biomechanical gradients for directed bone marrow stromal cell differentiation toward tendon and bone. Biomaterials 2010;31:7695-704.
44. Ragetly G, Griffon DJ, Chung YS. The effect of Type II collagen coating of chitosan fibrous scaffolds on mesenchymal stem cell adhesion and chondrogenesis. Acta Biomater 2010;6:3988-97.
45. Koga H, Engebretsen L, Brinchmann JE, Muneta T, Sekiya I. Mesenchymal stem cell-based therapy for cartilage repair: A review. Knee Surg Sports Traumatol Arthrosc 2009;17:1289-97.
46. Fuller JA, Ghadially FN. Ultrastructural observations on surgically produced partial-thickness defects in articular cartilage. Clin Orthop Relat Res 1972;86:193-205.
47. Convery FR, Akeson WH, Keown GH. The repair of large osteochondral defects. An experimental study in horses. Clin Orthop Relat Res 1972;82:253-62.
48. Lotz M. Cytokines in cartilage injury and repair. Clin Orthop Relat Res 2001;391:S108-15.
49. Minas T, Nehrer S. Current concepts in the treatment of articular cartilage defects. Orthopedics 1997;20:525-38.
50. Minas T. Autologous chondrocyte implantation for focal chondral defects of the knee. Clin Orthop Relat Res 2001;351:S349-61.
51. Peterson L, Minas T, Brittberg M, Nilsson A, Sjogren-Jansson E, Lindahl A. Two-to 9-year outcome after autologous chondrocyte transplantation of the knee. Clin Orthop Relat Res 2000;378:212-34.
52. Lee K, Hui JH, Song IC, Ardany L, Lee EH. Injectable mesenchymal stem cell therapy for large cartilage defects-a porcine model. Stem Cells 2007;25:2964-71.
53. Risbud M, Sittinger M. Tissue engineering: Advances in in vitro cartilage generation. Trends Biotechnol 2002;20:351-6.
54. Miyahara Y, Nagaya N, Kataoka M, Yanagawa B, Tanaka K, Hao H, et al. Monolayered mesenchymal stem cells repair scarred myocardium after myocardial infarction. Nat Med 2006;12:459-65.
55. Liu J, Hu Q, Wang Z, Xu C, Wang X, Gong G, et al. Autologous stem cell transplantation for myocardial repair. Am J Physiol Heart Circ Physiol 2004;287:H501-11.
56. Reinlib L, Field L. Cell transplantation as future therapy for cardiovascular disease?: A workshop of the national heart, lung, and blood institute. Circulation 2000;101:E182-7.
57. Amado LC, Saliaris AP, Schuleri KH, St John M, Xie JS, Cattaneo S, et al. Cardiac repair with intramyocardial injection of allogeneic mesenchymal stem cells after myocardial infarction. Proc Natl Acad Sci U S A 2005;102:11474-9.
58. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999;284:143-7.
59. Makino S, Fukuda K, Miyoshi S, Konishi F, Kodama H, Pan J, et al. Cardiomyocytes can be generated from marrow stromal cells in vitro. J Clin Invest 1999;103:697-705.
60. Tang, YL, Zhao Q, Zhang YC, Cheng L, Liu M, Shi J, et al. Autologous mesenchymal stem cell transplantation induce VEGF and neovascularization in ischemic myocardium. Regul Pept 2004;117:3-10.
61. Ratajczak MZ, Zuba-Surma EK, Shin DM, Ratajczak J, Kucia M. Very small embryonic-like (VSEL) stem cells in adult organs and their potential role in rejuvenation of tissues and longevity. Exp Gerontol 2008;43:1009-17.
62. Tang J, Xie Q, Pan G, Wang J, Wang M. Mesenchymal stem cells participate in angiogenesis and improve heart function in rat model of myocardial ischemia with reperfusion. Eur J Cardiothorac Surg 2006;30:353-61.
63. Oh H, Chi X, Bradfute SB, Mishina Y, Pocius J, Michael LH, et al. Cardiac muscle plasticity in adult and embryo by heart-derived progenitor. Ann N Y Acad Sci 2004;1015:182-9.
64. Toma C, Pittenger MF, Cahill KS, Byrne BJ, Kessler PD. Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation 2002;105:93-8.
65. Shake JG, Gruber PJ, Baumgartner WA, Senechal G, Meyers J, Redmond JM, et al. Mesenchymal stem cell implantation in a swine myocardial infarct model: Engraftment and functional effects. Ann Thorac Surg 2002;73:1919-25.
66. Lai R, Chen T, Lim S. Mesenchymal stem cell exosome: A novel stem cell-based therapy for cardiovascular disease. Regen Med 2011;6:481-92.
67. Wannemuehler T, Manukyan MC, Brewster BD, Rouch J, Poynter JA, Wang Y, et al. Advances in mesenchymal stem cell research in sepsis. J Surg Res 2012;173:113-26.
68. Mothe A, Tator C. Advances in stem cell therapy for spinal cord injury. J Clin Invest 2012;122:3824-34.
69. Dai L, Li HY, Guan LX, Ritchie G, Zhou JX. The therapeutic potential of bone marrow-derived mesenchymal stem cells on hepatic cirrhosis. Stem Cell Res 2009;2:16-25.
70. Dong S, Su S. Advances in mesenchymal stem cells combined with traditional Chinese medicine therapy for liver fibrosis. J Integr Med 2014;12:147-55.
71. Krasnodembskaya A, Song Y, Fang X, Gupta N, Serikov V, Lee JW, et al. Antibacterial effect of human mesenchymal stem cells is mediated in part from secretion of the antimicrobial peptide LL-37. Stem Cells 2010;28:2229-38.
72. Urbán V, Kiss J, Kovács J, Gócza E, Vas V, Monostori E, et al. Mesenchymal stem cells cooperate with bone marrow cells in therapy of diabetes. Stem Cells 2008;26:244-53.
73. Mounayar M, Magee C, Abdi R. Immunomodulation by mesenchymal stem cells: A potential therapeutic strategy for Type 1 diabetes. Diabetes 2008;57:1759-67.
74. Piero NM, Joan NM. Cancer: A molecular curse? Int J Curr Pharm Res 2015;7:1-3.
75. Jayaraman S, Variyar EJ. Evaluation of immunomodulatory and antioxidant activities of polysaccharides isolated from Callicarpa macrophylla Vahl. Int J Pharm Pharm Sci 2015;7:357-60.
76. Dwyer RM, Khan S, Barry FP, O’Brien T, Kerin MJ. Advances in mesenchymal stem cell-mediated gene therapy for cancer. Stem Cell Res Ther 2010;1:25.
77. Baksh D, Song L, Tuan R. Adult mesenchymal stem cells: Characterization, differentiation, and application in cell and gene therapy. J Cell Mol Med 2004;8:301-16.
78. Mohammadi M, Jaafari MR, Mirzaei HR, Mirzaei H. Mesenchymal stem cell: A new horizon in cancer gene therapy. Cancer Gene Ther 2016;23:285-6.
79. Wagle N, Nagarjuna S, Sudheer A, Roopesh C, Sapkota HP, Dangi NB, et al. Evaluation of immunomodulatory activity of petroleum ether extract of seeds of Pithecellobium Dulce in wistar rats. Int J Pharm Pharm Sci 2015;7:471-9.
80. Yagi H, Soto-Gutierrez A, Parekkadan B, Kitagawa Y, Tompkins RG, Kobayashi N, et al. Mesenchymal stem cells: Mechanisms of immunomodulation and homing. Cell Transplant 2010;19:667-79.
81. De Miguel M, Fuentes-Julián S, Blázquez-Martínez A, Pascual CY, Aller MA, Arias J, et al. Immunosuppressive properties of mesenchymal stem cells: Advances and applications. Curr Mol Med 2012;12:574-91.
82. Sun L, Akiyama K, Zhang H, Yamaza T, Hou Y, Zhao S, et al. Mesenchymal stem cell transplantation reverses multiorgan dysfunction in systemic lupus erythematosus mice and humans. Stem Cells 2009;27:1421-32.
83. Fierabracci A, Del Fattore A, Luciano R, Muraca M, Teti A, Muraca M. Recent advances in mesenchymal stem cell immunomodulation: The role of microvesicles. Cell Transplant 2015;24:133-49.
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.